5 completed, 5 terminated, 3 recruiting, 1 withdrawn. 14 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 5, Terminated 5, Recruiting 3, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Feraheme: new trials by email Literature Review of Feraheme trials Research Report on Feraheme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy Ferumoxytol - Epilepsy, Temporal Lobe | Phase 2 | Recruiting | University of Alberta | 50 | 2025-05-01 | 2026-05-08 |
| Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection - Prematurity, Iron-deficiency | Phase 2 | Recruiting | University of Washington | 120 | 2022-11-27 | 2026-05-26 |
| Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging - Glioblastoma | Phase 2 | Terminated | OHSU Knight Cancer Institute | 52 | 2017-12-20 | 2025-09-09 |
| Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging - Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7 | Phase 2 | Terminated | OHSU Knight Cancer Institute | 2 | 2017-11-03 | 2022-08-10 |
| Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors Ferumoxytol, Magnetic Resonance Imaging - Brain Neoplasm | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2017-10-20 | 2021-11-10 | |
| Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System Ferumoxytol, Gadolinium, Magnetic Resonance Imaging - Central Nervous System Neoplasm, Cranial Nerve Disorder | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 150 | 2017-10-06 | 2026-09-14 |
| Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS Ferumoxytol - AIDS Dementia Complex | Phase 2 | Completed | Beau Nakamoto | 30 | 2015-02-01 | 2017-10-27 |
| Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers Ferumoxytol, Magnetic Resonance Imaging (MRI) - Prostate Cancer, Bladder Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2014-05-15 | 2019-09-06 |
| Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery EPO, Feraheme - Anemia, Cardiovascular Disease | Phase 1 / Phase 2 | Terminated | University of Texas Southwestern Medical Center | 5 | 2013-04-09 | 2020-10-23 |
| Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer WB-DW-MR scan, 18-F-FDG PET scan, Ferumoxytol - Cancer | Phase 1 / Phase 2 | Completed | Stanford University | 158 | 2012-02-22 | 2026-10-06 |
| Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI Feraheme, Magnetic Resonance Imaging (MRI) scan - Bone Cancer, Chondrosarcoma | Phase 2 | Completed | Heike E Daldrup-Link | 32 | 2011-08-01 | 2023-12-27 |
| A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease Ferumoxytol, Iron Sucrose - Iron Deficiency, Anemia | Phase 2 | Completed | AMAG Pharmaceuticals, Inc. | 162 | 2010-03-01 | 2023-07-25 |
| Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging - Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 40 | 2006-11-16 | 2023-09-07 |
| MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation Ferumoxytol - Nervous System Diseases, Diagnostic Imaging | Phase 2 | Terminated | Oregon Health and Science University | 255 | 2004-07-01 | 2024-01-30 |
Anemia (3) · Anemia, Iron-Deficiency (3) · Brain Neoplasms (3) · Iron Deficiencies (2) · AIDS Dementia Complex (1) · Bone Neoplasms (1) · Cardiovascular Diseases (1) · Central Nervous System Neoplasms (1) · Chondrosarcoma (1) · Cranial Nerve Diseases (1) · Dementia (1) · Epilepsy, Temporal Lobe (1) · Glioblastoma (1) · Kidney Diseases (1) · Kidney Neoplasms (1)
OHSU Knight Cancer Institute (5) · AMAG Pharmaceuticals, Inc. (1) · Beau Nakamoto (1) · Heike E Daldrup-Link (1) · National Cancer Institute (NCI) (1) · Oregon Health and Science University (1) · Stanford University (1) · University of Alberta (1) · University of Texas Southwestern Medical Center (1) · University of Washington (1)
United States (12) · Canada (2) · Belgium (1) · Germany (1) · India (1) · Poland (1) · United Kingdom (1)
Beau Nakamoto, MD, PhD (1) · Donald Gross, MD (1) · Edward A Neuwelt (1) · Edward A Neuwelt, MD (1) · Edward Neuwelt (1) · Edward Neuwelt, MD (1) · Heike Daldrup-Link (1) · Heike E Daldrup-Link, MD (1) · Ismail B Turkbey, M.D. (1) · Kendell R German, MD (1) · Leslie Muldoon, Ph.D. (1) · Michael F Regner, MD (1) · Neyssa Marina, MD (1) · Philip E. Greilich, MD (1)
PMID 24458078, PMID 24559803, PMID 32368961, PMID 34870211, PMID 36999999, PMID 41430711
2009 (1), K08CA237809 (1), R01CA137488 (1), R01CA269231 (1), R01HD107003 (1), R01NS034608 (1), R21NS087951 (1)